M&T Bank’s Apellis Pharmaceuticals APLS Stock Holding History

M&T Bank’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,817	Closed	-$435K	–	1783
2026 Q1	$435K	Sell	10,817 -3,660	-25%	-$78.9K	﹤0.01%	1179
2025 Q4	$364K	Buy	14,477 +1,452	+11%	+$34.1K	﹤0.01%	1280
2025 Q3	$296K	Buy	+13,025	New	+$304K	﹤0.01%	1219
2025 Q1	–	Sell	-6,768	Closed	-$216K	–	1560
2024 Q4	$216K	Buy	+6,768	New	+$204K	﹤0.01%	1504
2024 Q3	–	Sell	-6,820	Closed	-$262K	–	1631
2024 Q2	$262K	Buy	6,820 +1,549	+29%	+$70.2K	﹤0.01%	1368
2024 Q1	$310K	Buy	5,271 +591	+13%	+$37.7K	﹤0.01%	1310
2023 Q4	$280K	Buy	+4,680	New	+$237K	﹤0.01%	1345

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

M&T Bank's APLS Position: Q2 2026 in Review

M&T Bank sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 10,817 shares — an estimated $435K sold.

M&T Bank first reported a position in APLS in Q4 2023 and held it in 7 quarters. The position peaked at $435K in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

M&T Bank reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
M&T Bank sold 10,817 Apellis Pharmaceuticals shares in Q2 2026, an estimated $435K.
M&T Bank first reported a position in Apellis Pharmaceuticals in Q4 2023 and held it in 7 quarters.
M&T Bank's Apellis Pharmaceuticals position peaked at $435K in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on M&T Bank's 13F filing for Q2 2026, filed 4 Aug 2026.